UPDATE: Barrington Research Raises Price Target on Thoratec to $38
According to Barrington Research, Thoratec (NASDAQ: THOR) price target is raised to $38.
Barrington Research said that THOR reported strong Q4/11 results with revenue up 12% to $109.4 million versus $97.6 million in Q4/10. “We are reiterating our OUTPERFORM rating and raising our target from $36 to $38 based on the company's technology and clinical leadership in the large and growing HF market.”
Thoratec closed on Friday at $34.19.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.